The increasing complexity of cancer chemotherapy heightens the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy. It will also serve as a review of various agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
LiM.C., HertzR., SpencerD.B.Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Exper Biol Med.1956; 93: 361–366.
2.
LurainJ.R.Advances in management of high-risk gestational trophoblastic tumors. J Reprod Med.2002; 47: 451–459.
Royal College of Obstetricians and Gynaecologists. The management of gestational trophoblastic neoplasia, guideline no. 38. February 2004. Available at: http://www.rcog.org.uk. Accessed May 28, 2006.
5.
SoperJ.T., MutchD.G., SchinkJ.C.Diagnosis and treatment of gestational trophoblastic disease: ACOG practice bulletin no. 53. Gynecol Oncol.2004; 93: 575–585.
6.
NewlandsE.S., BagshaweK.D., BegentR.H., RustinG.J., HoldenL., DentJ.Developments in chemotherapy for medium- and high-risk patients with gestational trophoblastic tumours (1979-1984). Br J Obstet Gynaecol.1986; 93: 63–69.
SchinkJ.C., SinghD.K., RademakerA.W., MillerD.S., LurainJ.R.Etoposide, methotrexate, actinomycin-D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease. Obstet Gynecol.1992; 80: 817–820.
9.
QuinnM., MurrayJ., FriedlanderM.. EMACO in high risk gestational trophoblast disease – the Australian experience. Aust N Z J Obstet Gynaecol.1994; 34: 90–92.
10.
EscobarP.F., LurainJ.R., SinghD.K., BozorgiK., FishmanD.A.Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy. Gynecol Oncol.2003; 91: 552–557.
11.
NewlandsE.S., BagshaweK.D., BegentR.H.J., RustinG.J., HoldenL.Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989. Br J Obstet Gynaecol.1991; 98: 550–557.
12.
SoperJ.T., EvansA.C., Clarke-PearsonD.L., BerchuckA., RodriguezG., HammondC.B.Alternating weekly chemotherapy with etoposidemethotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease. Obstet Gynecol.1994; 83: 113–117.
13.
BowerM., NewlandsE.S., HoldenL.. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol.1997; 15: 2636–2643.
14.
TrisselL.A., ZhangY., CohenM.R.The stability of diluted vincristine sulfate used as a deterrent to inadvertent intrathecal injection. Hosp Pharm.2001; 36: 740–745.
15.
National Comprehensive Cancer Network. Antiemesis. Version 2. 2006. Available at: http://www.nccn.org. Accessed May 29, 2006.
16.
KrisM.G., HeskethP.J., SomerfieldM.R.. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. Available at: http://www.asco.org. Accessed May 29, 2006.
17.
Multinational Association for Supportive Care in Cancer. Antiemetic Guidelines. 2005. Available at: http://www.mascc.org. Accessed May 29, 2006.
18.
StillwellT.J., BensonR.C.Jr. Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients. Cancer.1988; 61: 451–457.
ZanottiK.M., MarkhamM.Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf.2001; 24: 767–779.
21.
SmithT.J., KhatcheressianJ., LymanG.H.. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24. Published ahead of print on May 15, 2006. Available at: http://www.jco.org/cgi/doi/10.1200/JCO.2006.06.4451. Accessed June 1, 2006.
22.
National Comprehensive Cancer Network.Myeloid growth factors in cancer treatment. Version 2.2005. Available at http://www.nccn.org. Accessed June 1, 2006.
23.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49(9): 1796–1799.
24.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surg.1985; 75: 397–405.
25.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35: 57–74.
26.
PattersonW.P., ReamsG.P.Renal and electrolyte abnormalities due to chemotherapy. PerryM.C., ed, In: The Chemotherapy Sourcebook.3rd ed.Philadelphia, PA: Lippincott Williams and Wilkins; 2001; 494–504.
27.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21: 33–64.
28.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapy. Oncologist.2001; 6: 162–179.
